Literature DB >> 31119266

Oral anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1: a current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on Stroke.

Patrick Sulzgruber1, Sven Wassmann2,3, Anne Grete Semb4, Wolfram Doehner5,6, Petr Widimsky7, Thomas Gremmel1,8, Juan Carlos Kaski9, Gianluigi Savarese10, Giuseppe M C Rosano11,12, Claudio Borghi13, Keld Kjeldsen14,15, Christian Torp-Pedersen16,17, Thomas Andersen Schmidt18, Basil S Lewis19,20, Heinz Drexel21,22, Juan Tamargo23, Dan Atar24, Stefan Agewall24, Alexander Niessner1.   

Abstract

Oral anticoagulation in patients presenting with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1 (CHA2DS2-VASc of 2 in women) remains a challenging approach in clinical practice. Therapeutic decisions need to balance the individual benefit of reducing thromboembolic risk against the potential harm due to an increase in bleeding risk in this intermediate risk patient population. Within the current opinion statement of the European Society of Cardiology working group of cardiovascular pharmacotherapy and the European Society of Cardiology council on stroke the currently available evidence on the anti-thrombotic management in patients presenting with a CHA2DS2-VASc of 1 is summarized. Easily applicable tools for a personalized refinement of the individual thromboembolic risk in patients with atrial fibrillation and a CHA2DS2-VASc score of 1 that guide clinicians through the question whether to anticoagulate or not are provided. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author(s) 2019. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Atrial fibrillation ; CHA2DS2-VASc score ; Intermediate risk;  Anticoagulation

Mesh：

Substances：

Year:  2019        PMID： 31119266     DOI： 10.1093/ehjcvp/pvz016

Source DB:  PubMed          Journal:  Eur Heart J Cardiovasc Pharmacother


  16 in total

Review 1.  Can echocardiography improve the prediction of thromboembolic risk in atrial fibrillation? Evidences and perspectives.

Authors:  Antonella Tufano; Maurizio Galderisi
Journal:  Intern Emerg Med       Date:  2020-03-02       Impact factor: 3.397

Review 2.  The Impact of Sex and Gender on Stroke.

Authors:  Kathryn M Rexrode; Tracy E Madsen; Amy Y X Yu; Cheryl Carcel; Judith H Lichtman; Eliza C Miller
Journal:  Circ Res       Date:  2022-02-17       Impact factor: 17.367

3.  Left atrial strain measured by 4D Auto LAQ echocardiography is significantly correlated with high risk of thromboembolism in patients with non-valvular atrial fibrillation.

Authors:  Lili Chen; Chunquan Zhang; Jiangtao Wang; Liangyun Guo; Xiaolin Wang; Fengzhen Liu; Xia Li; Yu Zhao
Journal:  Quant Imaging Med Surg       Date:  2021-09

4.  Left Atrial Remodeling and Thromboembolic Risk in Patients With Atrial Fibrillation.

Authors:  Hyemoon Chung; Jung Myung Lee
Journal:  Int J Heart Fail       Date:  2022-01-31

5.  The personalized antithrombotic management of atrial fibrillation with intermediate thromboembolic risk: a case report.

Authors:  Andreas Hammer; Sebastian Schnaubelt; Alexander Niessner; Patrick Sulzgruber
Journal:  Eur Heart J Case Rep       Date:  2020-09-09

6.  Patient characteristics, adherence, and costs of oral anticoagulation therapy in non-valvular atrial fibrillation using the Dubai Real-World Claims Database.

Authors:  Moutaz El Kadri; Ahmed Ghorab; Jean Joury; Mohamed Farghaly; Nancy Awad; Badarinath Chickballapur Ramachandrachar; Ashok Natarajan
Journal:  Avicenna J Med       Date:  2021-04-19

7.  Cardiovascular care of patients with stroke and high risk of stroke: The need for interdisciplinary action: A consensus report from the European Society of Cardiology Cardiovascular Round Table.

Authors:  Wolfram Doehner; Mikael Mazighi; Bernd M Hofmann; Dominik Lautsch; Gerhard Hindricks; Erin A Bohula; Robert A Byrne; A John Camm; Barbara Casadei; Valeria Caso; Christophe Cognard; Hans-Christoph Diener; Matthias Endres; Patrick Goldstein; Alison Halliday; Jemma C Hopewell; Dejana R Jovanovic; Adam Kobayashi; Maciej Kostrubiec; Antonin Krajina; Ulf Landmesser; Hugh S Markus; George Ntaios; Francesca R Pezzella; Marc Ribo; Giuseppe Mc Rosano; Marta Rubiera; Mike Sharma; Rhian M Touyz; Petr Widimsky
Journal:  Eur J Prev Cardiol       Date:  2019-09-30       Impact factor: 7.804

8.  Does CHA2DS2-VASc score predict mortality in chronic kidney disease?

Authors:  Christos Goudis; Stylianos Daios; Panagiotis Korantzopoulos; Tong Liu
Journal:  Intern Emerg Med       Date:  2021-07-07       Impact factor: 3.397

9.  Does the CHA2DS2-VASc scale sufficiently predict the risk of left atrial appendage thrombus in patients with diagnosed atrial fibrillation treated with non-vitamin K oral anticoagulants?

Authors:  Anna Michalska; Iwona Gorczyca; Magdalena Chrapek; Agnieszka Kapłon-Cieślicka; Beata Uziębło-Życzkowska; Katarzyna Starzyk; Olga Jelonek; Monika Budnik; Monika Gawałko; Paweł Krzesiński; Agnieszka Jurek; Piotr Scisło; Janusz Kochanowski; Marek Kiliszek; Grzegorz Gielerak; Krzysztof J Filipiak; Grzegorz Opolski; Beata Wożakowska-Kapłon
Journal:  Medicine (Baltimore)       Date:  2020-06-19       Impact factor: 1.817

10.  LDL-C/HDL-C is associated with ischaemic stroke in patients with non-valvular atrial fibrillation: a case-control study.

Authors:  Xiao-Xue Zhang; Meng Wei; Lu-Xiang Shang; Yan-Mei Lu; Ling Zhang; Yao-Dong Li; Jiang-Hua Zhang; Qiang Xing; Zu Kela Tu-Erhong; Bao-Peng Tang; Xian-Hui Zhou
Journal:  Lipids Health Dis       Date:  2020-10-07       Impact factor: 3.876
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.